Press Releases April 7, 2026 08:00 PM

Pilgrim’s Pride Corporation to Host First Quarter Earnings Call on April 30, 2026

Pilgrim's Pride Schedules Q1 2026 Earnings Call for April 30

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
PPC

Pilgrim's Pride Corporation announced it will release its first quarter 2026 financial results after the U.S. market closes on April 29, 2026. The company will host an earnings call and webcast on April 30, 2026, to review the results with investors and analysts. The webcast will include prepared remarks and a Q&A session with management, with replay options available.

Pilgrim’s Pride Corporation to Host First Quarter Earnings Call on April 30, 2026
PPC
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Pilgrim's Pride operates protein processing plants and prepared foods facilities across multiple countries, impacting the food production and consumer goods sectors.
  • The Q1 earnings call provides transparency to investors on the company's financial health and operational performance for early 2026.
  • Prepared remarks and Q&A format indicate a standard disclosure process, aiming to maintain investor confidence and market clarity.

GREELEY, Colo., April 08, 2026 (GLOBE NEWSWIRE) -- Pilgrim’s Pride Corporation (NASDAQ: PPC) announced today that it will release its first quarter 2026 financial results after the U.S. market closes on Wednesday, April 29. The company’s executives will review the results on a conference call and webcast on Thursday, April 30, 2026, at 7:00 a.m. MT (9:00 a.m. ET). Prepared remarks regarding the company’s financial and operational results will be followed by a question and answer period with the Pilgrim’s executive management team. A press release and supplemental materials will be issued before the market opens that morning.

Investors and analysts may pre-register for the webcast to receive a unique PIN to gain immediate access to the call and bypass the live operator. Pre-registration may be completed at any time, including up to and after the call has begun, by accessing the company’s investor website at https://ir.pilgrims.com in the “Events & Presentations” section. Participants also can register for the conference call and webcast at https://dpregister.com/sreg/10208065/103bf7759a7.

Participants who would like to join the call but have not pre-registered can do so on the day of the event by dialing +1 (844) 883-3889 within the US, or +1 (412) 317-9245 internationally, and requesting the “Pilgrim’s Pride Conference.” To submit a question to management during the call, participants must be logged in via telephone.

The webcast will be available for replay on Pilgrim’s website two hours after the call concludes and will remain available through May 30, 2026. Alternatively, the telephone replay may be accessed by dialing +1 (855) 669-9658 in the US, or +1 (412) 317-0088 internationally, and requesting conference number 2463710, which will be available through July 30, 2026.

About Pilgrim’s Pride Corporation

Pilgrim’s employs approximately 63,000 people and operates protein processing plants and prepared foods facilities in 14 states, Puerto Rico, Mexico, the U.K., the Republic of Ireland and continental Europe. The company’s primary distribution is through retailers and foodservice distributors. For more information, please visit www.pilgrims.com

Contact
Andrew Rojeski
Head of Strategy, Investor Relations & Sustainability
Phone: 970 506 7783
[email protected]  


Risks

  • Financial results may reveal operational or market challenges in the protein processing and prepared foods industry influencing investor sentiment.
  • External factors like supply chain disruptions or commodity price fluctuations could affect upcoming financial performance.
  • Uncertainty around demand shifts in retail and foodservice sectors could impact revenue forecasts and stock performance.

More from Press Releases

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026 ROMA Green Finance Establishes Dedicated Artificial Intelligence and High-Performance Computing Infrastructure Investment Vertical Jun 12, 2026